INGENIA Therapeutics
About
INGENIA Therapeutics is a research-driven biotechnology company developing treatments for diseases caused by inflamed and leaky blood vessels. Its technology aims to halt, reverse and restore blood vessel disorders by modifying clinically validated endothelial and immune signaling pathways. The pipeline targets vascular diseases, including eye conditions such as neovascular age-related macular degeneration and diabetic macular edema, as well as vasculitis-associated disorders.
The company was incorporated in Boston in 2018 and secured exclusive patent rights from KAIST and the Institute for Basic Science in Korea the following year. In 2022 it signed an out-licensing and co-development agreement for its eye drug candidate IGT-427 with EyeBio, and after MSD acquired EyeBio the compound joined MSD’s core pipeline as MK-8748. A second candidate, IGT-303, has entered clinical trials in Australia, New Zealand and South Korea.
What to Know
- INGENIA listed on the KOSDAQ market of the Korea Exchange in 2026.
- IGT-427 has advanced to a Phase 2b/3 clinical trial for neovascular AMD.
- The company has assembled three scientific advisory boards.
- It is a member of the Charles River Regional Chamber.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.